Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights

Caplin Point Q3FY22 PAT at Rs 74.95 cr.

Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.

Caplin Point Labs posts Q2FY22 PAT at Rs 74.98 Cr

The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021

Caplin Point Lab's subsidiary receives nod from Brazil's ANVISA for sterile injectable manufacturing site

The approval allows it to market its products in the country

Caplin Point Laboratories posts consolidated PAT in Q1FY22 at Rs 70.85 Cr

EPS climbs to Rs 9.25 for the quarter

Caplin Steriles receives USFDA approval for Calcium Gluconate Injection

Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million

Caplin Steriles gets USFDA approval for potassium phosphates injection

Caplin Steriles gets FDA approval for desmopressin

Desmopressin Acetate Injection is primarily used to treat central diabetes insipidus, haemophilia A, and von Willebrand disease

Caplin Steriles gets USFDA approval for Sodium Phosphate injection

Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake

Caplin Steriles gets FDA final approval for Acetaminophen Injection, infusion bags

Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older